BPTES treatment significantly altered the levels of a number of metabolites in both breast cancer cell lines, and such altered levels clearly indicate the cells' sensitivity to the glutaminase inhibitor BPTES (Figures 2, 5). This evidence concerns the gene GLS and breast carcinoma.